GSK in Lung Drug Deal with Apeiron
By Taskin Ahmed
Pharma Deals Review: Vol 2010 Issue 2 (Table of Contents)
Published: 9 Feb-2010
DOI: 10.3833/pdr.v2010.i2.1311 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
GlaxoSmithKline (GSK), a leader in the treatment of respiratory diseases, has obtained the rights to a Phase I enzyme biotherapeutic produced by Vienna-based Apeiron Biologics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS